EP0668774A4 - Interleukinrezeptor gerichtete moleküle zur behandlung der entzündlichen arthritis. - Google Patents

Interleukinrezeptor gerichtete moleküle zur behandlung der entzündlichen arthritis.

Info

Publication number
EP0668774A4
EP0668774A4 EP19920912075 EP92912075A EP0668774A4 EP 0668774 A4 EP0668774 A4 EP 0668774A4 EP 19920912075 EP19920912075 EP 19920912075 EP 92912075 A EP92912075 A EP 92912075A EP 0668774 A4 EP0668774 A4 EP 0668774A4
Authority
EP
European Patent Office
Prior art keywords
treatment
inflammatory arthritis
targeted molecules
interleukin receptor
receptor targeted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19920912075
Other languages
English (en)
French (fr)
Other versions
EP0668774A1 (de
Inventor
Thasia G Woodworth
Jean C Nichols
Patricia A Bacha
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seragen Inc
Original Assignee
Seragen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seragen Inc filed Critical Seragen Inc
Publication of EP0668774A4 publication Critical patent/EP0668774A4/de
Publication of EP0668774A1 publication Critical patent/EP0668774A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP92912075A 1991-05-03 1992-05-04 Interleukinrezeptor gerichtete moleküle zur behandlung der entzündlichen arthritis Withdrawn EP0668774A1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US69548091A 1991-05-03 1991-05-03
US695480 1991-05-03
US87652192A 1992-04-30 1992-04-30
US876521 1992-04-30
PCT/US1992/003714 WO1992019259A1 (en) 1991-05-03 1992-05-04 Interleukin receptor targeted molecules for treatment of inflammatory arthritis

Publications (2)

Publication Number Publication Date
EP0668774A4 true EP0668774A4 (de) 1995-04-25
EP0668774A1 EP0668774A1 (de) 1995-08-30

Family

ID=27105578

Family Applications (1)

Application Number Title Priority Date Filing Date
EP92912075A Withdrawn EP0668774A1 (de) 1991-05-03 1992-05-04 Interleukinrezeptor gerichtete moleküle zur behandlung der entzündlichen arthritis

Country Status (7)

Country Link
EP (1) EP0668774A1 (de)
JP (1) JPH06510750A (de)
AU (1) AU665763B2 (de)
BR (1) BR9205967A (de)
CA (1) CA2108886A1 (de)
NO (1) NO933960L (de)
WO (1) WO1992019259A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608693B2 (en) * 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
AR092177A1 (es) 2012-08-21 2015-03-25 Sanofi Sa Metodos para tratar o prevenir asma administrando un antagonista de il-4r
TWI633891B (zh) 2013-06-04 2018-09-01 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑以治療過敏及增強過敏原－特異之免疫療法的方法
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
KR20160120735A (ko) 2014-02-28 2016-10-18 리제너론 파아마슈티컬스, 인크. Ｉｌ-4ｒ 길항제의 투여에 의한 피부 감염의 치료 방법
KR20170081262A (ko) 2014-11-14 2017-07-11 사노피 바이오테크놀로지 Ｉｌ-4ｒ 길항제의 투여에 의한, 비용종을 동반한 만성 부비동염의 치료 방법
WO2018045130A1 (en) 2016-09-01 2018-03-08 Regeneron Pharmaceuticals, Inc. Methods for preventing or treating allergy by administering an il-4r antagonist
TWI784988B (zh) 2016-12-01 2022-12-01 美商再生元醫藥公司 治療發炎症狀的方法
WO2019028367A1 (en) 2017-08-04 2019-02-07 Regeneron Pharmaceuticals, Inc. METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES
PT3515465T (pt) 2017-08-18 2024-03-04 Regeneron Pharma Métodos para o tratamento de uma dermatite atópica grave mediante a administração de um inibidor de il-4r
KR20200081429A (ko) 2017-10-30 2020-07-07 사노피 바이오테크놀로지, 소시에떼 빠르 악씨옹 셍쁠리피에 Il-4r 길항제를 투여하여 천식을 치료 또는 예방하는 방법
US11292847B2 (en) 2018-05-13 2022-04-05 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an IL-4R inhibitor
CA3132587A1 (en) 2019-03-21 2020-09-24 Regeneron Pharmaceuticals, Inc. Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
CA3147068A1 (en) 2019-08-05 2021-02-11 Regeneron Pharmaceuticals, Inc. Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r antagonist

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992006117A1 (en) * 1990-09-28 1992-04-16 Seragen, Inc. Inhibiting unwanted immune responses

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE448386B (sv) * 1978-10-18 1987-02-16 Sandoz Ag Nya cyklosporinderivat, forfarande for framstellning av dem samt farmaceutisk komposition innehallande dem
US5080898A (en) * 1982-05-12 1992-01-14 The University Hospital Enzymatically active toxin coupled to a cell-specific ligand
ATE25197T1 (de) * 1982-05-12 1987-02-15 Harvard College Hybridproteinekodierende fusionierte gene, sie enthaltende klonierungsvektoren und deren verwendung.
IL89504A0 (en) * 1988-03-08 1989-09-10 Univ Wyoming Diphtheria toxin derivative,process for the preparation thereof and pharmaceutical composition containing the same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992006117A1 (en) * 1990-09-28 1992-04-16 Seragen, Inc. Inhibiting unwanted immune responses

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
54TH ANNUAL MEETING OF THE AMERICAN COLLEGE OF RHEUMATOLOGY, SEATTLE, WASHINGTON, USA, OCTOBER 27-NOVEMBER 1, 1990. ARTHRITIS RHEUM 33 (9 SUPPL.). 1990. S105. CODEN: ARHEAW ISSN: 0004-3591 *
55TH ANNUAL MEETING OF THE AMERICAN COLLEGE OF RHEUMATOLOGY, BOSTON, MASSACHUSETTS, USA, NOVEMBER 17-21, 1991. ARTHRITIS RHEUM 34 (9 SUPPL.). 1991. S89. CODEN: ARHEAW ISSN: 0004-3591 *
ARTHRITIS RHEUM 32 (4). 1989. 386-392. CODEN: ARHEAW ISSN: 0004-3591 *
CHEMICAL ABSTRACTS, vol. 114, no. 9, 4 March 1991, Columbus, Ohio, US; abstract no. 79863 *
CORY A. WATERS ET AL.: "INTERLEUKIN 2 RECEPTOR-TARGETED CYTOTOXICITY. RECEPTOR BINDING REQUIREMENTS FOR ENTRY OF A DIPHTHERIA TOXIN-RELATED INTERLEUKIN 2 FUSION PROTEIN INTO CELLS.", EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 20, pages 785 - 791 *
DATABASE BIOSIS BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; BACHA P ET AL: "IMPACT OF A SPECIFIC RECEPTOR-DIRECTED CYTOTOXIN DAB-486IL-2 ON RAT ADJUVANT ARTHRITIS." *
DATABASE BIOSIS BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; FORTE S ET AL: "IMPACT OF A SPECIFIC RECEPTOR-DIRECTED CYTOTOXIN DAB-486IL-2 ON RAT ADJUVANT ARTHRITIS." *
DATABASE BIOSIS BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; LAFFON A ET AL: "VERY LATE ACTIVATION ANTIGEN ON SYNOVIAL FLUID T CELLS FROM PATIENTS WITH RHEUMATOID ARTHRITIS AND OTHER RHEUMATIC DISEASES." *
DATABASE BIOSIS BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; SEWELL K L ET AL: "IMPROVEMENT IN REFRACTORY RHEUMATOID ARTHRITIS BY INTERLEUKIN-2 RECEPTOR TARGETED THERAPY." *
DATABASE MEDLINE US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; *
GOLDSMITH M.F.: "EXCITEMENT OVER IMMUNOMODULATION INUNDATES CLINICAL RESEARCH MEETINGS [NEWS]", JAMA, vol. 265, no. 21, 5 June 1991 (1991-06-05), pages 2768 - 2773 *
GRAILER ALAN P. ET AL.: "INHIBITION OF HUMAN ANTIGEN-SPECIFIC MEMORY B CELL RESPONSE IN VITRO BY A DIPHTERIA TOXIN-RELATED INTERLEUKIN 2 FUSION PROTEIN.", CELL. IMMUNOL., vol. 132, no. 2, pages 481 - 493, XP024001012, DOI: doi:10.1016/0008-8749(91)90044-C *
MEETING OF THE ASSOCIATION OF AMERICAN PHYSICIANS, THE AMERICAN SOCIETY FOR CLINICAL INVESTIGATION, AND THE AMERICAN FEDERATION FOR CLINICAL RESEARCH, WASHINGTON, D.C., USA, MAY 4-7, 1990. CLIN RES 38 (2). 1990. 276A. CODEN: CLREAS ISSN: 0009-9279 *
See also references of WO9219259A1 *

Also Published As

Publication number Publication date
WO1992019259A1 (en) 1992-11-12
NO933960L (no) 1993-12-28
JPH06510750A (ja) 1994-12-01
BR9205967A (pt) 1994-07-26
AU1992792A (en) 1992-12-21
NO933960D0 (no) 1993-11-02
EP0668774A1 (de) 1995-08-30
CA2108886A1 (en) 1992-11-04
AU665763B2 (en) 1996-01-18

Similar Documents

Publication Publication Date Title
EP0603194A4 (de) Zum rezeptor des epidermalen wachstumsfaktors zielgesteuerte moleküle zur behandlung entzündlicher arthritis.
EP0558317A3 (en) Cauterising apparatus
EP0668774A4 (de) Interleukinrezeptor gerichtete moleküle zur behandlung der entzündlichen arthritis.
ZA93811B (en) Methods of treating inflammatory dermatoses.
EP0460912A3 (en) Medicaments for the treatment of sexual disorder
IL110204A0 (en) Novel indolene derivatives, processes for their preparation and their use for the treatment of cns disorders
SG43952A1 (en) Process for the purification of chlorofluorocarbons
EP0673384A4 (de) Polypeptide nützlich in der behandlung von entzündlichen erkrankungen.
EP0723460A4 (de) Gentherapie für das nervensystems
GB2262036B (en) Medicaments for treating inflammatory conditions or for analgesia
EP0563239A4 (de) Zerstümmeltes interleukin-1-rezeptor-gen zur behandlung von arthritis.
EP0510503A3 (en) Process for the treatment of surfaces
GB9420740D0 (en) Sequence of the hyaluronan receptor gene
GR3018814T3 (en) Process for the purification of 1,1,1,2-tetrafluoroethane.
DZ2012A1 (fr) Benzamides pour le traitement de dégénérescences neurologiques.
EP0452906A3 (en) Apparatus for alternately arranging the direction of an article
SG49017A1 (en) Polypeptides useful for treating inflammatory disorders
PH31659A (en) Therapeutic nucleotides.
HU911045D0 (en) Apparatus for the preloading of prefabricated bars
AU2959892A (en) Apparatus for thermal treatment of the prostate
EP0584251A4 (de) Gegen den cytokin-rezeptor gerichtete moleküle zur behandlung des neoplasmatischen zellwachstums.
FR2688001B1 (fr) Procede de preparation de p-aminophenols.
EP0583136A3 (en) Piperidino-3,4-dihydrocarbostyryl compounds for the treatment of ischemic disorders
NO974956D0 (no) Terapeutisk sammensetning for artritis
GB2289046B (en) An effluent treatment system

Legal Events

Date Code Title Description
A4 Supplementary search report drawn up and despatched
AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19931124

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE

17Q First examination report despatched

Effective date: 19970402

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19981210